UnknownPhase 4NCT05135442
Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP
Studying Thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking Union Medical College Hospital
- Principal Investigator
- tienan zhuPeking Union Medical College Hospital
- Intervention
- Bortezomib Injection(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- Peking Union Medical College Hospital, Beijing, (Select), China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05135442 on ClinicalTrials.govOther trials for Thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06928233Association of TNFAIP3 With Immune-mediated TTPFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT07205861Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA CenterAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT06376786Italian iTTP RegistryFondazione Luigi Villa
- RECRUITINGNCT06945861Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)University Hospital, Rouen
- RECRUITINGNCT05950750Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter StudyTurkish Hematology Association
- RECRUITINGNCT05571774Construction of a Database for TTPThe First Affiliated Hospital of Soochow University
- ACTIVE NOT RECRUITINGPHASE3NCT04683003A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraTakeda